Tag Directory / BIOTECH     showing 41–60 of 85



HPV cancer vaccine slows tumor growth and extends survival in preclinical model / Medical Express

medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 14, 2026, 5:21 am / permalink 19182 / 5 stories in 25 days


FDA clears 1st blood test for Alzheimer’s in primary care / Beckers

Ella Jeffries / beckershospitalreview - The first FDA-cleared blood test to assess Alzheimer’s disease in primary care is now available for patients age 55 and older with symptoms of cognitive decline. The test aims to help clinicians rule out Alzheimer’s by identifying individuals unlikely to …

#healthcare #publichealth #governmentpolicy #biotech #fda


Saturday, February 14, 2026, 4:21 am / permalink 19180 / 18 stories in 25 days


Studies test whether gene-editing can fix high cholesterol. For now, take your medicine / Medical Express

medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 14, 2026, 3:21 am / permalink 19179 / 4 stories in 25 days


Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment


Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days


Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO / Endpoints

Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...

#healthcare #pharmaceuticals #biotech #drugdevelopment


Saturday, February 14, 2026, 3:20 am / permalink 19177 / 3 stories in 25 days


BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 25 days


Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization / Nature

Baris R. Mutlu / nature - Nature Medicine, Published online: 12 February 2026; doi:10.1038/s41591-026-04207-xThe authors developed a microfluidic device, FIND-Chip, designed to automate and enhance oocyte recovery from follicular fluid, a process traditionally done manually. When …

#healthcare #biotech #infanthealth


Friday, February 13, 2026, 9:23 am / permalink 19125 / 4 stories in 26 days


FDA refuses to review Moderna flu vaccine / Beckers

Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Wednesday, February 11, 2026, 10:25 am / permalink 19026 / 15 stories in 28 days


AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo / Endpoints

Anna Brown / endpoints - The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Monday, February 9, 2026, 12:21 am / permalink 18917 / 5 stories in 4 wks


World Cancer Day: A Global Call to Awareness and Action 2026, Part 2 / OncoDaily

oncodaily - World Cancer Day is observed annually on February 4 and was established in 2000 at the World Summit Against Cancer for the New Millennium in Paris. The initiative was led […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment


Early Detection & Access Initiatives


Other Cancer News


Research and Treatment Advances


World Cancer Day Global Events


All Other Stories


Saturday, February 7, 2026, 3:21 pm / permalink 18896 / 162 stories in 4 wks


#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial / Endpoints

Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 7, 2026, 3:21 am / permalink 18873 / 2 stories in 4 wks


Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery / OncoDaily

oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 7, 2026, 1:21 am / permalink 18871 / 2 stories in 4 wks


Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, January 31, 2026, 2:22 pm / permalink 18622 / 9 stories in 5 wks


FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Saturday, January 31, 2026, 7:22 am / permalink 18610 / 4 stories in 5 wks


#JPM26: Day 3 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...

#obesity #healthcare #pharmaceuticals #weightloss #biotech #drugdevelopment #digitalhealth


Saturday, January 17, 2026, 7:21 pm / permalink 18138 / 28 stories in 7 wks


Ancient Wolf Stomach Reveals Remnants of 14,400-Year-Old Woolly Rhino Genome / Discover

discovermagazine - Learn about the woolly rhino genome that was recovered from a wolf's stomach, providing insight on the extinct species' genetic health.

#biotech


Saturday, January 17, 2026, 1:21 pm / permalink 18133 / 3 stories in 7 wks


#JPM26: Day 1 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s day 1 at the JP Morgan Healthcare Conference, and the mood heading into the week is one of cautious optimism. Biotech fundraising was off to a hot start in 2026. There ...

#healthcare #pharmaceuticals #biotech #digitalhealth


Saturday, January 17, 2026, 8:21 am / permalink 18125 / 9 stories in 7 wks


FDA rejects cancer therapy for rare post-transplant disease / Beckers

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 7 wks


AI Model Identifies How Every Country Can Improve Its Cancer Outcomes / ESMO

esmo - For the first time, researchers have used machine learning – a type of artificial intelligence (AI) – to identify the most important drivers of cancer survival in nearly all the countries in the world

#healthcare #publichealth #governmentpolicy #biotech


AI Innovations in Cancer


Clinical Advances & Trials


Other Developments


Policy & Advocacy Collaborations


All Other Stories


Thursday, January 15, 2026, 4:21 pm / permalink 17950 / 38 stories in 7 wks


Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech


Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 7 wks


Back to Top


BIOTECH Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.